Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Jul 19, 2011


Thomas Schinecker has been appointed as lifecycle leader for sequencing and president of Roche's 454 Life Sciences, effective Aug. 1. He will replace 454's current president and CEO, Chris McLeod, who will retire in September.

Schinecker, who will report to Robert Yates, head of Roche Applied Science, is currently the general manager of Sweden for Roche Diagnostics. Previously, he held leadership positions in sales and marketing at Roche Diagnostics Austria. He holds a PhD in oncology from New York University.

Two Life Technologies executives have recently left the company. Kip Miller has left his position as president of the firm's genetic systems division in April. He is currently spending time with his family prior to planning his next steps. Previously, Miller led Invitrogen's biodiscovery division.

Kevin McKernan has also left Life Technologies. Most recently, he was vice president of advanced research R&D. Previously, he was the president of Agencourt Personal Genomics, which was acquired by Applied Biosystems in 2006.

Applied Biosystems and Invitrogen merged in 2008 to form Life Technologies.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.